A number of firms have modified their ratings and price targets on shares of Medpace (NASDAQ: MEDP) recently:
- 9/20/2024 – Medpace had its price target lowered by analysts at Robert W. Baird from $430.00 to $413.00. They now have an “outperform” rating on the stock.
- 9/18/2024 – Medpace was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 9/11/2024 – Medpace had its “outperform” rating reaffirmed by analysts at William Blair.
- 9/5/2024 – Medpace was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 8/9/2024 – Medpace was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 8/1/2024 – Medpace is now covered by analysts at Truist Financial Co.. They set a “hold” rating and a $415.00 price target on the stock.
- 8/1/2024 – Medpace was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
Medpace Stock Performance
Medpace stock traded down $1.11 during mid-day trading on Monday, hitting $364.59. 93,031 shares of the company traded hands, compared to its average volume of 251,395. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The stock has a market cap of $11.30 billion, a price-to-earnings ratio of 37.17, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35. The stock has a fifty day moving average price of $378.15 and a 200-day moving average price of $391.82.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business’s revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the business posted $1.93 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current year.
Hedge Funds Weigh In On Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Stories
- Five stocks we like better than Medpace
- Learn Technical Analysis Skills to Master the Stock Market
- The Average 401k Balance by Age Explained
- Using the MarketBeat Dividend Yield Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.